The only other thing i would like to see is pyc give access to Ms Soucek (assuming she is interested) to our libraries so she could trial our fpp with her omomyc. Obviously we trialled omomyc ourselves and this generated significant interest. Surely if she could replicate her earlier results without "genetically engineered" mouse model but by using our fpp instead we could talk about finance after. If she were able to demonstrate results in a standard cancer mouse model she may be able to generate a client willing to finance both omomyc and the conjugated fpp required to make it work? I hope we are not stuck on this front because we are trying to get cash for allowing library use. Rather let her get the results first then talk money?? I assume we were able to use omomyc for free as long as we didnt sell it so same for them. Based in europe they could surely generate more interest than we did with imyc.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)